An Innovative Journal in the Field of Radiology
Authors
The aim of the present study was to investigate the potential improvement in detection rate of nodal and distant metastasis and the resultant impact on clinical management by PET-based diagnostic work up in comparison with conventional imaging modalities in various clinical settings in patients with breast cancer.
Of a total 256 patients with breast cancer who were referred to PET/CT division, MasihDaneshvari Hospital between May 2013 and Mar. 2016, 123 cases were included. Definitely-positive PET/CT findings in primary site as well as N1 (level I, II ipsilateral axillary nodes), N2 (ipsilateral internal mammary), N3 (ipsilateral internal mammary+ level I, II ipsilateral axillary, ipsilateral level II axillary, ipsilateral supraclavicular node) and distant metastasis (distant node and viscera) and related impact on clinical management (upstaging or downstaging) were retrospectively identified from the report archive and then compared with the results of baseline imaging modalities including CT scan, sonography, bone scan, C-X ray, MRI, MRM and mammography obtained from patient medical records. The most typical imaging pattern was considered as the reference standard. Indeterminant and equivocal PET positive lesion were not included in the study.
Fourteen (11.38%) and 109 (88.62%) out of 123 patients were referred for staging and restaging/recurrence/surveillance, respectively. Mean age were 51.42 (34 - 62) and 52.66 (29 - 79) for staging and restaging groups, respectively. In staging group, 18 F FDG PET/CT recognized definitely positive additional nodal involvement in 21.4% of patients all of them related to the supraclavicular level and hence result in change N staging to N3. Additional metastatic lesions on a per lesion-basis and a per organ-basis were identified as 28.6% and 14.3%, repsectively. A significant change in patient management occurred in 42.9% (35.7% upstaging, 7.2% down staging). In restaging group, locoregional detection rate in biopsy proved recurrence was 100%. Additional nodal detection and the resultant change in N staging were 29.6% and 28.7%, respectively. Supraclavicular node detection contribute in 53.12% of overall change in N staging followed by axillary node and internal mammary equally (15.62%). Additional metastatic lesions on a per lesion-basis and per organ-basis were identified in 53.2% and 44%, respectively. Ultimate change in patients management was found in 42.9%.
18 F FDG PET/CT is a valuable imaging tool in initial and subsequent treatment strategy in patients with breast cancer by providing additional nodal and distant metastasis and may have the promising future potential to be as the imaging modality of choice for accurate assessment of disease extension in breast cancer in routine clinical practice.
© 2017, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Yazdani S, Fallah H, Rezaie F. Application of PET/CT in Oncologic Imaging. I J Radiol. 2017;14(Special Issue):e48282. doi: https://doi.org/10.5812/iranjradiol.48282
Bakhshayeshkaram M. Role of Positron Emission Tomography–Computed Tomography in Pulmonary Neoplasms. I J Radiol. 2014;11(30th Iranian Congress of Radiology):e93645. doi: https://doi.org/10.5812/iranjradiol.21330
Buyukdereli G, Aktar Y, Kara E, Uguz A, Sonmez H. Role of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Evaluation of Cytologically Indeterminate Thyroid Nodules. I J Radiol. 2016;13(1):e21186. doi: https://doi.org/10.5812/iranjradiol.21186
Noda Y, Goshima S, Kawada H, Kawai N, Koyasu H, et al. HER2-Positive Breast Cancer: Tumor-to-Liver SUV Ratio is the Best Parameter for Detection in F-18 FDG-PET/CT. I J Radiol. 2017;14(3):e41928. doi: https://doi.org/10.5812/iranjradiol.41928
Hinev A, Chaushev B, Klisarova A. FDG PET/CT in Prostate Cancer: A Valuable Method to Detect the Primary and Metastatic Tumor Sites and to Monitor Cancer Response to Hormonal Therapy. Nephro-Urol Mon. 2012;4(4):644-645. doi: https://doi.org/10.5812/numonthly.4539
More by these authors
Last Update: 1 week ago
Last Update: 1 week ago
Last Update: 1 week ago
Last Update: 6 days ago
Last Update: 2 days ago
Last Update: 3 days ago
